CN117379459A - Composition for treating melanoma - Google Patents
Composition for treating melanoma Download PDFInfo
- Publication number
- CN117379459A CN117379459A CN202310811028.2A CN202310811028A CN117379459A CN 117379459 A CN117379459 A CN 117379459A CN 202310811028 A CN202310811028 A CN 202310811028A CN 117379459 A CN117379459 A CN 117379459A
- Authority
- CN
- China
- Prior art keywords
- dendritic cells
- composition
- melanoma
- fangchinoline
- treating melanoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000001441 melanoma Diseases 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 45
- IIQSJHUEZBTSAT-VMPREFPWSA-N fangchinoline Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(O)C1=C23 IIQSJHUEZBTSAT-VMPREFPWSA-N 0.000 claims abstract description 35
- IIQSJHUEZBTSAT-UHFFFAOYSA-N fangchinoline Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(O)C1=C23 IIQSJHUEZBTSAT-UHFFFAOYSA-N 0.000 claims abstract description 35
- 239000003814 drug Substances 0.000 claims abstract description 10
- 229940079593 drug Drugs 0.000 claims abstract description 9
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 claims abstract description 6
- WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 210000001616 monocyte Anatomy 0.000 claims description 6
- 208000030381 cutaneous melanoma Diseases 0.000 claims description 5
- 201000003708 skin melanoma Diseases 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 15
- 239000000427 antigen Substances 0.000 abstract description 10
- 102000036639 antigens Human genes 0.000 abstract description 10
- 108091007433 antigens Proteins 0.000 abstract description 10
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 abstract description 9
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 8
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 230000000259 anti-tumor effect Effects 0.000 abstract description 3
- 230000001363 autoimmune Effects 0.000 abstract description 3
- 210000000987 immune system Anatomy 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000004083 survival effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 13
- 238000011081 inoculation Methods 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 5
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000032972 Conjunctival malignant melanoma Diseases 0.000 description 2
- 206010066384 Conjunctival melanoma Diseases 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 230000037451 immune surveillance Effects 0.000 description 2
- 201000002576 malignant conjunctival melanoma Diseases 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003127 anti-melanomic effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 230000000385 effect on melanoma Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000011502 immune monitoring Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000003446 pia mater Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000001745 uvea Anatomy 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a composition for treating melanoma, and belongs to the technical field of medicines; the composition for treating melanoma provided by the invention comprises tetrandrine and dendritic cells. According to the composition for treating melanoma, the fangchinoline and the dendritic cells are subjected to synergistic action, so that on one hand, the fangchinoline can enhance the antigen cross presentation function of the dendritic cells, activate the immune system to clear tumors, realize autoimmune treatment, and on the other hand, the dendritic cells can further enhance the anti-tumor effect of the fangchinoline; thereby obtaining excellent melanoma treatment effect; the composition for treating melanoma has low toxic and side effects, can be used for preparing a pharmaceutical preparation, can be used in combination with other common medicines or routes for treating melanoma, improves the treatment effect and prolongs the survival time of patients.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a composition for treating melanoma.
Background
Melanoma is a skin tumor with extremely high malignancy, and the morbidity and mortality rate rise year by year, which causes serious threat to human life health. Melanoma is often found in the skin, and can also occur in various parts or tissues such as mucous membranes, uvea oculi, pia mater, etc. Although there are treatment schemes aiming at melanoma at present, although melanoma at different positions has certain similarity, the treatment schemes cannot be used equally; for example, conjunctival melanoma and melanoma are malignant tumors, but the occurrence positions of the malignant tumors are different, the conjunctival melanoma is malignant tumor occurring on conjunctiva, and the melanoma is generally malignant tumor occurring on skin, mucous membrane, fundus and the like, and the treatment scheme cannot be simply migrated due to the different occurrence positions.
Immune surveillance is an important way for eliminating cancerous cells in the human body, and when the immune surveillance function is impaired, malignant transformation of melanocytes cannot be recognized and eliminated in time, resulting in immune escape and occurrence of melanoma. Dendritic Cells (DCs) as the strongest antigen presenting cells have a key role in human tumor immune monitoring; the absence of cross-presentation function of DC antigens is a significant cause of immune escape of tumor cells. Therefore, it is of great importance to find compounds that enhance the cross-presentation function of DC antigens.
Disclosure of Invention
The present invention aims to overcome the above-mentioned disadvantages of the prior art and to provide a composition for treating melanoma.
To achieve the above object, in a first aspect of the present invention, there is provided a composition for treating melanoma, the composition comprising fangchinoline and dendritic cells.
According to the composition for treating melanoma, provided by the invention, the synergistic effect is achieved through the fangchinoline and the dendritic cells (DC cells), so that an excellent melanoma treatment effect is obtained, and the obtained composition can obviously reduce the volume and weight of tumors in animal experiments; specifically, the fangchinoline and the dendritic cells act synergistically, on one hand, the fangchinoline can enhance the antigen cross-presenting function of the dendritic cells, activate the immune system to clear tumors, realize autoimmune treatment, avoid immune related side effects possibly caused by exogenous immunotherapy, and on the other hand, the dendritic cells can further enhance the anti-melanoma effect of the fangchinoline; meanwhile, the fangchinoline is a natural compound, and the dendritic cells are immune cells, so that the fangchinoline and the fangchinoline have good biocompatibility and lower toxic and side effects.
As a preferred embodiment of the composition of the present invention, the ratio of dendritic cells to fangchinoline is (1X 10) 6 -1×10 7 ) The following steps: (5-15) mg.
Preferably, the ratio of dendritic cells to fangchinoline in the composition is (2×10) 6 -5×10 6 ) The following steps: (8-12) mg.
More preferably, the ratio of dendritic cells to fangchinoline in the composition is 2.5X10 6 The following steps: 10mg.
The inventor researches find that the ratio of the dendritic cells to the fangchinoline in the provided composition can also influence the performance of the product, and when the ratio of the dendritic cells to the fangchinoline is within the range given by the invention, the dendritic cells and the fangchinoline can exert more excellent synergistic effect, and the obtained product has more excellent treatment effect on melanoma.
As a preferred embodiment of the composition of the present invention, the dendritic cells are monocyte-derived dendritic cells.
The inventor researches and discovers that when dendritic cells from different sources are selected, the effect of the obtained product is better.
As a preferred embodiment of the composition of the present invention, the melanoma is skin melanoma.
Although melanoma at different positions has certain similarity, the treatment modes also have differences due to different positions, and the inventor researches show that the composition provided by the invention has better treatment effect on skin melanoma.
In a second aspect of the invention, the invention provides a pharmaceutical formulation for the treatment of melanoma, the pharmaceutical formulation comprising fangchin alkali and dendritic cells.
As a preferred embodiment of the pharmaceutical preparation of the present invention, the dendritic cells are monocyte-derived dendritic cells.
As a preferred embodiment of the pharmaceutical formulation according to the invention, the melanoma is cutaneous melanoma.
As a preferred embodiment of the pharmaceutical preparation of the present invention, the dosage of fangchinoline is (5-15) mg/kg, and the dosage of dendritic cells is (1X 10) 6 -1×10 7 ) And (3) each kg.
Preferably, in the pharmaceutical preparation, the dosage of fangchinoline is (8-12) mg/kg, and the dosage of dendritic cells is (2×10) 6 -5×10 6 ) And (3) each kg.
More preferably, in the pharmaceutical preparation, the dosage of the fangchinoline is 10mg/kg, and the dosage of the dendritic cells is 2.5X10 6 And (3) each kg.
As a preferred embodiment of the pharmaceutical formulation according to the invention, the pharmaceutical formulation further comprises a pharmaceutically acceptable carrier.
As a preferred embodiment of the pharmaceutical preparation of the present invention, the pharmaceutical preparation is in the form of an injection.
In a third aspect of the invention, the invention provides a pharmaceutical composition for treating melanoma, comprising the composition for treating melanoma of the invention, and other drugs commonly used for treating melanoma.
As a preferred embodiment of the pharmaceutical composition of the present invention, the other commonly used drugs for treating melanoma include at least one of paclitaxel, cisplatin, temozolomide, dacarbazine, carboplatin, and vemurafenib.
As a preferred embodiment of the pharmaceutical composition of the present invention, the dendritic cells are monocyte-derived dendritic cells.
As a preferred embodiment of the pharmaceutical composition according to the present invention, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
In a fourth aspect of the invention, the invention provides the use of a combination of fangchinoline and dendritic cells for the preparation of a medicament for the treatment of melanoma.
As a preferred embodiment of the use according to the invention, the dendritic cells are monocyte-derived dendritic cells.
As a preferred embodiment of the use according to the invention, the melanoma is skin melanoma.
Compared with the prior art, the invention has the beneficial effects that:
according to the composition for treating melanoma, the fangchinoline and the dendritic cells are subjected to synergistic action, so that on one hand, the fangchinoline can enhance the antigen cross presentation function of the dendritic cells, activate the immune system to clear tumors, realize autoimmune treatment, and on the other hand, the dendritic cells can further enhance the anti-tumor effect of the fangchinoline; thereby obtaining excellent melanoma treatment effect; the composition for treating melanoma has low toxic and side effects, can be used for preparing a pharmaceutical preparation, can be used in combination with other common medicines or routes for treating melanoma, improves the treatment effect and prolongs the survival time of patients.
Drawings
FIG. 1 is a graph showing the effect of fangchinoline on antigen cross-presentation function in example 1;
FIG. 2 is a graph showing the comparison of the results of the tumor blocks in example 2.
Detailed Description
For a better description of the objects, technical solutions and advantages of the present invention, the present invention will be further described with reference to the following specific examples.
Unless otherwise specified, reagents and equipment used in the present invention are all conventionally available.
Example 1
The embodiment of the invention explores the influence of fangchinoline on antigen cross presentation function, and specifically comprises the following steps:
the experimental steps are as follows: the effect of fangchinoline (Fan) on MutuDC antigen cross presentation was flow tested using the DC cell line MutuDC. Grouping: negative, igG, ctrl, fan. Mu.M, six-well plate MutuDC plate 100 ten thousand/well, next day with Fan and OVA protein, four wells with OVA protein 100ug/mL, last group with Fan 5. Mu.M, 24H after action, on-machine detection, OVA257-264 (SIINFEKL) peptide is MHC class I molecule (H-2K in mice) b ) Restricted OVA polypeptide epitope, mutuDC cell surface H-2K b How much of the/SIINFEKL complex represents the size of the MutuDC antigen cross-presentation capacity. In this experiment we used specifically recognized H-2K b After staining, the fluorescent antibody of the SIINFEKL complex is subjected to flow detection, and the stronger the fluorescence intensity is, the stronger the MutuDC antigen cross-presentation capability is represented.
The obtained results are shown in figure 1, and the dendritic cells treated by the fangchinoline can obviously enhance the presentation of OVA proteins.
Example 2
The embodiment of the invention explores the treatment effect of tetrandrine and dendritic cells on mouse melanoma, and specifically comprises the following steps:
(1) Inoculating a C57BL/6 mouse through B16 cells (mouse melanoma cells) to construct a mouse transplantation tumor model;
(2) Mice with successfully constructed melanoma transplantation tumor models were grouped into Ctrl, DC, fan, DC +Fan groups of 8 mice each. Ctrl is a blank group, neither vaccinated with DC cells nor subjected to Fan treatment; example 1 both DC cells were seeded and Fan treated; comparative example 1 was only DC cell seeded, without Fan treatment; comparative example 2 was treated with Fan alone and was not inoculated with DC cells. Three days before DC cell inoculation, the corresponding groups of example 1 and comparative example 2 were subjected to intraperitoneal injection of corresponding doses of fangchinoline, three consecutive days, once a day, and the comparative example 1 and the blank group were injected with physiological saline at a dose of 10mg/kg at the same time; three days after continuous injection, the groups corresponding to example 1, comparative example 1 were dosed with DC cells; example 1 and comparative example 2 the daily injection of fangchinoline according to the table dose was continued until the material was obtained, the tumor volume was recorded daily on day 6, the tumor volume of each group was measured first on day 15, and then the tumor was taken out and photographed.
TABLE 1
| Fanghexiline base | Monocyte-derived DC cells | |
| Blank group | 0 | 0 |
| Example 1 | 10mg/kg | 2.5×10 6 Individual/kg |
| Comparative example 1 | 0 | 2.5×10 6 Individual/kg |
| Comparative example 2 | 10mg/kg | 0 |
(3) Measuring tumor volume and recording every day from the 6 th day of inoculation, taking materials 15 days after inoculation, dissecting tumor, photographing and measuring tumor weight of tumor, and recording in table 2, wherein nd represents the nth day after inoculation of melanoma cells, tumor weight is the weight after 15 days of inoculation of melanoma cells, dissecting tumor, cleaning and absorbing water; the values are all average values of each group
TABLE 2
| 0d(mm 3 ) | 6d(mm 3 ) | 10d(mm 3 ) | 15d(mm 3 ) | Tumor weight (g) | |
| Blank group | 0 | 30.75 | 196 | 927 | 1.2539 |
| Example 1 | 0 | 9.26 | 66 | 269 | 0.7348 |
| Comparative example 1 | 0 | 25 | 193 | 967 | 1.4089 |
| Comparative example 2 | 0 | 34 | 104 | 951 | 1.4076 |
As can be seen from Table 2, when the technical scheme of the invention is adopted (example 1), the growth rate of the tumor can be obviously controlled, the tumor volume after inoculation is slowly increased, and the average volume of the tumor at 15d after inoculation is 269mm 3 The average tumor weight is 0.735g, and compared with a blank group, the volume reduction amplitude is more than 70 percent, and the tumor weight reduction amplitude is more than 40 percent; it can be seen from example 1 and comparative examples 1 to 2 that the antitumor effect could not be achieved without adding fangchinoline or dendritic cells; wherein fig. 2 is a photograph of melanoma pieces in a blank group (Ctrl), example 1 (fan+dc), comparative example 1 (DC) and comparative example 2 (Fan), which were photographed 15 days later when the materials were taken. The visual observation of the figure shows that the tumor volume can be effectively reduced only under the technical scheme provided by the invention, and the excellent treatment effect is achieved.
Finally, it should be noted that the above-mentioned embodiments illustrate rather than limit the scope of the invention, and that those skilled in the art will understand that changes can be made to the technical solutions of the invention or equivalents thereof without departing from the spirit and scope of the technical solutions of the invention.
Claims (10)
1. A composition for treating melanoma, comprising fangchinoline and dendritic cells.
2. The composition of claim 1, wherein the ratio of dendritic cells to fangchinoline is (1 x 10) 6 -1×10 7 ) The following steps: (5-15) mg.
3. The composition of claim 1, wherein the dendritic cells are monocyte-derived dendritic cells.
4. The composition of claim 1, wherein the melanoma is skin melanoma.
5. A pharmaceutical formulation for treating melanoma, comprising fangchinoline and dendritic cells.
6. The pharmaceutical formulation according to claim 5, wherein the dosage of fangchinoline is (5-15) mg/kg and the dosage of dendritic cells is (1 x 10) 6 -1×10 7 ) And (3) each kg.
7. The pharmaceutical formulation of claim 5, further comprising a pharmaceutically acceptable carrier.
8. The pharmaceutical formulation of claim 5, wherein the pharmaceutical formulation is in the form of an injection.
9. A pharmaceutical composition for treating melanoma, comprising the composition for treating melanoma according to claim 1, and other drugs commonly used for treating melanoma.
10. The application of the combined drug of the tetrandrine and the dendritic cells in preparing the drugs for treating melanoma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310811028.2A CN117379459A (en) | 2023-07-04 | 2023-07-04 | Composition for treating melanoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310811028.2A CN117379459A (en) | 2023-07-04 | 2023-07-04 | Composition for treating melanoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117379459A true CN117379459A (en) | 2024-01-12 |
Family
ID=89461917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310811028.2A Pending CN117379459A (en) | 2023-07-04 | 2023-07-04 | Composition for treating melanoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117379459A (en) |
-
2023
- 2023-07-04 CN CN202310811028.2A patent/CN117379459A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60032622T2 (en) | COMPOSITION AND METHOD FOR CANCER ANTIGEN IMMUNOTHERAPY | |
| KR102008535B1 (en) | Immunogenic composition for immune system modulation and use thereof, method for treating and preventing diseases, method for inducing cell regeneration and method for restoring immune response | |
| Corbett et al. | Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure | |
| EP0726772B1 (en) | A method for sensitization of cancer cells for killer cell mediated lysis | |
| EP0433765A1 (en) | The use of immunomodulants as synergistic agents of chemotherapeutics in tumor therapy | |
| Wang et al. | Targeting macrophage anti-tumor activity to suppress melanoma progression | |
| van der Meer | The effects of recombinant interleukin-1 and recombinant tumor necrosis factor on non-specific resistance to infection | |
| CN105983097B (en) | Anti-tumor preparation and preparation method thereof | |
| Schwarzenberg et al. | Human toxicology of BCG applied in cancer immunotherapy | |
| CN117379459A (en) | Composition for treating melanoma | |
| KR102115468B1 (en) | Use of Mycobacterium paragordonae for anti-cancer immunotherapy | |
| Kurata et al. | Suppressed tumor growth and metastasis by vitamin A+ BCG in Lewis lung tumor bearing mice | |
| EP1815856A2 (en) | A cancer vaccine | |
| Tzai et al. | Modulation of antitumor immunity of tumor-bearing mice with low-dose cyclophosphamide | |
| Duenas-Gonzalez et al. | A pilot study of perilymphatic leukocyte cytokine mixture (IRX-2) as neoadjuvant treatment for early stage cervical carcinoma: preliminary report | |
| RU2782931C2 (en) | Indol-3-carboxic acid derivatives with anti-tumor activity | |
| Krosnick et al. | Studies of the mechanisms of toxicity of the administration of recombinant tumor necrosis factor α in normal and tumor-bearing mice | |
| CN111388665B (en) | Compound for treating tumor and preparation and application thereof | |
| KR100703570B1 (en) | Subcutaneously-administered ganglioside-based vaccine compositions | |
| WO2000032212A1 (en) | Lak activity potentiator orginating in shiitake mushroom hyphae extract and lak activity potentiating preparations containing the same | |
| Kushwaha | Immunomodulators as therapeutic agent | |
| Barnett et al. | 290 DEPLETING REGULATORY T CELLS IS ASSOCIATED WITH IMPROVED IMMUNITY AND TUMOR CLEARANCE IN HUMAN CANCER | |
| Robinson et al. | Results of postoperative treatment of colorectal cancer by radiotherapy, chemotherapy and immunotherapy | |
| Mansour et al. | Effect of methotrexate on the response of rat lymphocytes to phytohaemagglutinin | |
| Gallagher et al. | Efficacy of adjuvant interleukin-2 after excision of BALB/c fibrosarcomas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |